**Supplemental material**

Supplemental table 1: Factors associated with VTE by univariable analysis in UHBFT patients

Supplemental table 2: UNC Kidney Centre patient demographics in relation to CMV serostatus

Supplemental table 3: Comparison between UNK Kidney Centre patients that experienced a VTE episode during follow up versus those that did not

**Supplemental table 1: Factors associated with VTE by univariable analysis in UHBFT patients:**

|  |  |  |
| --- | --- | --- |
| **Variable** | **HR (Confidence interval)** | **P value** |
| PR3 versus MPO disease | 1.226 (.610-2.463) | 0.567 |
| Creatinine at diagnosis umol/L (IQR)  | 1.001 (1.000-1.001) | 0.135 |
| Urine ACR at diagnosis mg/mmol (IQR) | 1.001 (0.999-1.002) | 0.299 |
| Serum albumin at diagnosis g/L (IQR) | 0.951 (0.902-1.003) | 0.067 |
| Hb at diagnosis g/L (IQR) | 0.992 (0.980-1.004) | 0.183 |
| VTE event pre-AAV diagnosis | 2.476 (0.593-10.349) | 0.214 |
| Malignancy at diagnosis of AAV | 1.370 (0.184-10.182) | 0.759 |
| Malignancy at diagnosis of VTE or end of f/u | 0.422 (0.101-1.772) | 0.239 |
| Warfarin at diagnosis of AAV | 2.422 (0.329-17.827) | 0.385 |

**Supplemental table 2: UNC Kidney Centre patient demographics in relation to CMV serostatus:**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **All Patients n=68 (IQR)** | **CMV status** |
| **CMV+ve patients n= 40** | **CMV-ve patients n= 28** | **P value** |
| Median age at diagnosis (years) | 61 (47-71) | 66 (52-74) | 51 (37-65) | <0.001 |
| Male gender | 40 (59%) | 24 (60%) | 16 (57%) | 0.814 |
| PR3 +veMPO +ve | 27 (40%)41 (60%) | 13 (33%)27 (67%) | 14 (50%)14 (50%) | 0.147 |
| *Ethnicity:*WhiteBlack Hispanic | 61 (90%)5 (7%)2 (3%) | 135 (87%)3 (8%)2 (5%) | 26 (93%)2 (7%)0 (0%) | 0.483 |
| Median creatinine at diagnosis (umol/L)  | 184 (84-389) | 210 (84-466) | 165 (84-293) | 0.386 |
| Dialysis requirement at diagnosis or during follow up | 15 (22%) | 12 (30%) | 3 (11%) | 0.059 |
| Median duration of follow up (years) | 1.6 (1.1-2.6) | 1.6 (1.2-2.3) | 1.7 (1.1-2.8) | 0.994 |
| Median CRP at diagnosis mg/L (IQR)\* | 31 (4-126) | 31 (5-138) | 44 (2-126) | 0.618 |
| Median serum albumin at diagnosis g/L (IQR) | 33 (28-38) | 35 (29-40) | 30 (27-35) | 0.094 |

**Supplemental table 3: Comparison between UNC Kidney Centre patients that experienced a VTE episode during follow up versus those that did not:**

|  |  |
| --- | --- |
| **Characteristic** | **VTE status** |
| **Patients with no VTE n=62** | **Patients with VTE n=6** | **P value** |
| Median age at diagnosis in years (IQR) | 61 (46-69) | 67 (46-82) | 0.331 |
| Male gender | 35 (57%) | 5 (83%) | 0.201 |
| PR3 +veMPO +ve | 24 (39%)38 (61%) | 3 (50%)3 (50%) | 0.589 |
| Caucasian ethnicity | 55 (89%) | 6 (100%) | 0.385 |
| CMV seropositive | 34 (55%) | 6 (100%) | 0.032 |
| Dialysis requirement at diagnosis or during follow up | 12 (19%) | 3 (50%) | 0.139 |
| Median creatinine at diagnosis umol/L (IQR)  | 175 (82-375) | 442 (144-531) | 0.198 |
| Median serum albumin at diagnosis g/L (IQR) | 33 (28-38) | 31 (25-41) | 0.664 |
| Median Hb at diagnosis in g/L (IQR) | 106 (88-124) | 94 (86-108) | 0.328 |